ArticleGastroenterology2007
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.
Article in Gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 99 citations in OpenAlex.
- Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.World journal of gastroenterology · 2012Trial
- Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.World journal of gastroenterology · 2011Trial
- S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.Gastroenterology · 2011Trial
- Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.Hepatology (Baltimore, Md.) · 2007Trial
- The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- MicroRNA-122 in patients with hepatitis B and hepatitis B virus-associated hepatocellular carcinoma.Journal of gastrointestinal oncology · 2019Review
- [Relationship between the suppressor of cytokine signaling 3 expression and antiviral efficacy of nucleos(t)ide and interferon alpha therapy for chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Article
- Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice.The Journal of biological chemistry · 2017Article
- Kidney-Replenishing Herb Induces SOCS-3 Expression via ERK/MAPK Pathway and Improves Growth of the First-Trimester Human Trophoblast Cells.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?Cellular and molecular life sciences : CMLS · 2016Review
- Host restriction factors for hepatitis C virus.World journal of gastroenterology · 2016Review
- The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor α Agonist.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2015Article
- CD4 T-cell transcriptome analysis reveals aberrant regulation of STAT3 and Wnt signaling pathways in rheumatoid arthritis: evidence from a case-control study.Arthritis research & therapy · 2015Article
- Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response.PloS one · 2015Article
- Expression of selected genes in liver biopsy specimens in relation to early virological response in patients with chronic hepatitis C with HCV mono- and HIV/HCV co-infection.Archives of virology · 2014Article
- Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.Science (New York, N.Y.) · 2014Article
- Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?World journal of gastroenterology · 2013Review
- SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin.Journal of clinical immunology · 2013Article
- SOCS, inflammation, and cancer.JAK-STAT · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsApproximately half of hepatitis C virus (HCV)-infected patients do not respond to current interferon (IFN)-alpha combination therapy. To understand IFN-alpha resistance in vivo, we examined the dynamic responses to both type I and type II IFNs, human IFN (hIFN)-alpha, -gamma, and consensus IFN, in the chimpanzee model.
methodsNaive and HCV-infected chimpanzees were treated with 3 forms of hIFNs in vivo. Quantitative real-time polymerase chain reaction was performed to evaluate the expression of IFN-stimulated genes (ISGs) in both peripheral blood mononuclear cells and liver to compare the responses to hIFN between naive and infected chimpanzees. The hepatic expression of IFN signaling components and inhibitory regulators including suppressor of cytokine signaling 3 (SOCS3) were assessed. SOCS3 expression was also evaluated in the liver of HCV-infected patients undergoing IFN treatment.
resultsThe in vivo responses to all 3 hIFNs were much lower in the HCV-infected chimpanzees than those in the naive chimpanzees. This defect was particularly evident in the liver because induction of hepatic ISGs was barely detectable in the infected animals. Following IFN administration, the expression of SOCS3 was significantly up-regulated, possibly through induction of interleukin-6, in the liver of HCV-infected chimpanzees. HCV-infected humans also showed a differential pattern of hepatic SOCS3 expression in response to IFN that is associated with treatment response.
conclusionsOur data indicate a predominantly defective hepatic response to IFN in HCV-infected chimpanzees, which is probably mediated through the activation of SOCS3 and may explain the nonresponse of many HCV patients to IFN-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.